Extended Data Table 1.
Patient demographics and efficacy by cohort CI, confidence interval; ORR, objective response rate; PFS, progression-free survival.
| Characteristic | HER2 | HER3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Breast (n=25) |
Lung (n=26) |
Bladder (n=16) |
Colorectal (n=12) |
Biliary
tract (n=9) |
Cervical (n=5) |
Endometrial (n=7) |
Gastro
esophageal (n=5) |
Ovarian (n=4) |
NOS (n=16) |
NOS (n=16) |
|
| Median (range), years | 57.0 (37–80) | 62.0 (46–74) | 65.0 (48–83) | 65.0 (30–81) | 66.0 (57–78) | 49.0 (42–56) | 57.0 (54–74) 5 | 67.0 (36–70) | 56.5 (38–58) | 59.0 (32–80) | 66.0 (39–82) |
| <65 years, n (%) | 19 (76.0) | 18 (69.2) | 8 (50.0) | 6 (50.0) | 2 (22.2) | 5 (100) | (71.4) | 1 (20.0) | 4 (100) | 13 (81.3) | 7 (43.8) |
| ≥65 years, n (%) | 6 (24.0) | 8 (30.8) | 8 (50.0) | 6 (50.0) | 7 (77.8) | 0 (0) | 2 (28.6) | 4 (80.0) | 0 (0) | 3 (18.8) | 9 (56.3) |
| Sex, n (%) | |||||||||||
| Female | 24 (96.0) | 17 (65.4) | 3 (18.8) | 6 (50.0) | 5 (55.6) | 5 (100) | 7 (100) | 2 (40.0) | 4 (100) | 7 (43.8) | 12 (75.0) |
| Male | 1 (4.0) | 9 (34.6) | 13 (81.3) | 6 (50.0) | 4 (44.4) | 0 (0) | 0 (0) | 3 (60.0) | 0 (0) | 9 (56.3) | 4 (25.0) |
| ECOG PS, n (%) | |||||||||||
| 0 | 7 (28.0) | 11 (42.3) | 6 (37.5) | 5 (41.7) | 2 (22.2) | 1 (20.0) | 2 (28.6) | 0 (0) | 0 (0) | 3 (18.8) | 1 (6.3) |
| 1 | 17 (68.0) | 14 (53.8) | 10 (62.5) | 7 (58.3) | 6 (66.7) | 4 (80.0) | 5 (71.4) | 5 (100) | 4 (100) | 11 (68.8) | 12 (75.0) |
| 2 | 1 (4.0) | 1 (3.8) | 0 (0) | 0 (0) | 1 (11.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (12.5) | 3 (18.8)’ |
| Prior systemic lines, n (%) | 0 (0) | 1 (3.8) | 1 (6.3) | 0 (0) | 1 (11.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (6.3) | 0 (0) |
| None | 3 (12.0) | 12 (46.2) | 2 (12.5) | 4 (33.3) | 3 (33.3) | 0 (0) | 1 (14.3) | 2 (40.0) | 0 (0) | 6 (37.5) | 1 (6.3) |
| 1 | 2 (8.0) | 6 (23.1) | 9 (56.3) | 3 (25.0) | 2 (22.2) | 3 (60.0) | 2 (28.6) | 1 (20.0) | 0 (0) | 2 (12.5) | 11 (68.8) |
| 2 | 20 (80.0) | 7 (26.9) | 4 (25.0) | 5 (41.7) | 3 (33.3) | 2 (40.0) | 4 (57.1) | 2 (40.0) | 4 (100) | 7 (43.8) | 4 (25.0) |
| ≥3 | |||||||||||
| Median time from metastasis to enrolment, years (range) | 2.64 (0.1–15.0) |
0.83 (0.1–3.1) |
0.69 (0.2–2.3) |
1.14 (0.0–2.7) |
1.00 (0.0–2.8) |
1.40 (0.3–4.5) |
0.43 (0.2–4.4) |
0.80 (0.4–4.3) |
7.54 (1.1–7.7) |
1.35 (0.0–5.4) |
1.13 (0.3–4.5) |
|
| |||||||||||
| Outcome | HER2 | HER3 | |||||||||
|
|
|||||||||||
| Breast (n=25) |
Lung (n=26) |
Bladder (n=16) |
Colorectal (n=12) |
Biliary tract (n=9) |
Cervical (n=5) |
Endometrial (n=7) |
Gastroesophageal (n=5) |
Ovarian (n=4) |
NOS (n=16) |
NOS (n=16) |
|
|
| |||||||||||
| ORR at week 8, n
(%) [95% CI] |
8
(32.0) [14.9–53.5] |
1
(3.8) [0.1–19.6] |
0
(0.0) [0.0–20.6] |
0
(0.0) [0.0–26.5] |
2
(22.2) [2.8–60.0] |
1
(20.0) [0.5–71.6] |
0
(0.0) [0.0–41.0] |
0
(0.0) [0.0–52.2] |
0
(0.0) [0.0–60.2] |
1
(6.3) [0.2–30.2] |
0
(0.0) [0.0–20.6] |
| ORR, n
(%) [95% CI] |
6
(24.0) [9.4–45.1] |
1
(3.8) [0.1–19.6] |
0
(0.0) [0.0–20.6] |
0
(0.0) [0.0–26.5] |
0
(0.0) [0.0–33.6] |
1
(20.0) [0.5–71.6] |
0
(0.0) [0.0–41.0] |
0
(0.0) [0.0–52.2] |
0
(0.0) [0.0–60.2] |
0
(0.0) [0.0–20.6] |
0
(0.0) [0.0–20.6] |
| Clinical benefit rate, n
(%) [95% CI] |
10
(40.0) [21.1–61.3] |
11
(42.3) [23.4–63.1] |
3
(18.8) [4.0–45.6] |
1
(8.3) [0.2–38.5] |
3
(33.3) [7.5–70.1] |
3
(60.0) [14.7–94.7] |
2
(28.6) [3.7–71.0] |
1
(20.0) [0.5–71.6] |
0
(0.0) [0.0–60.2] |
3
(18.8) [4.0–45.6] |
2
(12.5) [1.6–38.3] |
| Median PFS, months | 3.5 | 5.5 | 1.8 | 1.8 | 2.8 | 20.1 | 2.6 | 1.7 | 2.1 | 1.9 | 1.7 |